UPB Upstream Bio, Inc.
Financings ·
Upstream Bio signed a sales agreement with Leerink Partners LLC on March 26, 2026 that lets it sell up to $150,000,000 of common stock on the Nasdaq market. Leerink may earn a commission of up to 3.0% of gross proceeds, and cash used in operations rose to $133.3 million in 2025.
We have not published a story on Upstream Bio yet. When there is news, it will appear here.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Its candidate, verekitug, is a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor. The company describes verekitug as the only known antagonist of the TSLP receptor currently in clinical development. Upstream reported positive top-line results in its Phase 2 chronic rhinosinusitis with nasal polyps (CRSwNP) trial in September 2025 and in its Phase 2 severe asthma trial in February 2026. A Phase 2 trial in chronic obstructive pulmonary disease (COPD) began in July 2025. The company plans to start Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027, with quarterly at-home administration. Three Phase 1 trials have been completed for verekitug across a total of 120 participants. The filing compares verekitug with tezepelumab, a TSLP ligand antibody marketed by Amgen and AstraZeneca, and states that no head-to-head clinical studies against tezepelumab have been conducted. Upstream also says it intends to develop verekitug for other TSLP-driven diseases.
| Product or program | What it is | Stage |
|---|---|---|
| Verekitug | TSLP receptor monoclonal antibody for severe asthma, CRSwNP and COPD | Phase 2 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $2.9 million | $2.4 million |
| Research and development | $136.8 million | $63.0 million |
| Net income (loss) | -$143.4 million | -$62.8 million |
| Cash from operations | -$133.3 million | -$59.2 million |
| Cash and equivalents | $101.6 million | $325.9 million |
| Short-term investments | $239.9 million | $144.6 million |
Our latest story on this, dated Mar 26, 2026: "Upstream Bio sets up $150,000,000 at-the-market stock program with Leerink". The story links the filing or release it is based on. Read the story.
Upstream Bio, Inc. trades under the ticker UPB on NASDAQ.
Upstream Bio, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Upstream Bio, Inc. is 2022626. Its filings are on SEC EDGAR.
54,771,041 shares as of 2026-08-04, per the cover page of its 10-Q filed 2026-08-11.
Our directory records Upstream Bio, Inc. under United States.
Our directory classifies Upstream Bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Upstream Bio, Inc. is US91678A1079.
aibio.space lists Upstream Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Its candidate, verekitug, is a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor.
Verekitug: TSLP receptor monoclonal antibody for severe asthma, CRSwNP and COPD Stage: Phase 2.
$2.9 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Upstream Bio, Inc. reported a net loss of $143.4 million for the fiscal year ended Dec 31, 2025, and used $133.3 million of cash in operations, per its annual report to the SEC.
$136.8 million in the fiscal year ended Dec 31, 2025, per its annual report.
Reported a financing. SEC Form 424B5. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio